Alethia is developing innovative therapeutic approaches in areas of unmet medical needs, capitalizing on its capacity to identify and validate disease-specific targets for the development of highly focused monoclonal antibody-based therapeutics. The company is currently focusing on cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss.
Location: Canada, Quebec, Montreal
Total raised: $9.22M
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.09.2010 | Series A | $9.22M | - |
Mentions in press and media 3
| Date | Title | Description | Source |
| 30.10.2023 | Alethia Raises $50 Million With a Beverage Focus | - | labusiness... |
| 02.11.2012 | Alethia Biotherapeutics Closes Financing | Alethia Biotherapeutics Inc., a Montréal, Québec, Canada-based biotechnology company focusing on the... | finsmes.co... |
| 08.09.2010 | Alethia Biotherapeutics Closes C$9.6M Series A Round of Fina... | Alethia Biotherapeutics Inc., a Montreal, Canada-based biopharmaceutical company focused on the deve... | finsmes.co... |